Systemic Janus Kinase Inhibitor Treatment for Vitiligo: An Evidence-Based Review
收藏NIAID Data Ecosystem2026-05-02 收录
官方服务：
资源简介：
Vitiligo is an immune-mediated condition characterized by melanocyte loss. While topical Janus kinase inhibitors (JAKi) have recently been FDA-approved for refractory nonsegmental vitiligo, use of systemic JAKi remains novel. This systematic review summarizes evidence regarding this indication.
创建时间：
2024-09-10
